Therapeutic aptamers: Developmental potential as anticancer drugs

BMB Reports

Volumn 48, Issue 4, 2015, Pages 234-237

  Lee, Ji Won ^a   Kim, Hyun Jung ^a   Heo, Kyun ^a  

^a National Cancer Center   (South Korea)

Author keywords

Application; Aptamer; Cancer; Oligonucleotide; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; CXCL12 PROTEIN, HUMAN; OLIGONUCLEOTIDE; SINGLE STRANDED DNA; STROMAL CELL DERIVED FACTOR 1;

ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DESIGN; HUMAN; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CHEMOKINE CXCL12; CLINICAL TRIALS AS TOPIC; DNA, SINGLE-STRANDED; DRUG DESIGN; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES;

EID: 84929301851     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2015.48.4.277     Document Type: Review

References (45)

1. Scott AM, Wolchok JD and Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12, 278-287
2. Liu JKH (2014) The history of monoclonal antibody development-Progress, remaining challenges and future innovations. Ann Med Surg 3, 113-116
3. Chames P, Van Regenmortel M, Weiss E and Baty D (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157, 220-233
4. Tabrizi M, Bornstein GG and Suria H (2010) Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 12, 33-43
5. Miller MJ, Foy KC and Kaumaya PT (2013) Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med 15, 166-176
6. Jain RK and Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7, 653-664
7. Beckman RA, Weiner LM and Davis HM (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170-179
8. Sung HJ, Choi S, Lee JW et al (2014) Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8. Biomaterials 35, 578-589
9. Kim YH, Sung HJ, Kim S et al (2011) An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Cancer Lett 313, 76-83
10. Tuerk C and Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510
11. Keefe AD, Pai S and Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9, 537-550
12. Kong HY and Byun J (2013) Nucleic Acid aptamers: new methods for selection, stabilization, and application in biomedical science. Biomol Ther 21, 423-434
13. Sun H, Zhu X, Lu PY, Rosato RR, Tan W and Zu Y (2014) Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids 3, e182
14. Dong Y, Xu Y, Yong W, Chu X and Wang D (2014) Aptamer and its potential applications for food safety. Crit Rev Food Sci Nutr 54, 1548-1561
15. Song KM, Lee S and Ban C (2012) Aptamers and Their Biological Applications. Sensors (Basel) 12, 612-631
16. Tan W, Wang H, Chen Y et al (2011) Molecular aptamers for drug delivery. Trends Biotechnol 29, 634-640
17. Pendergrast PS, Marsh HN, Grate D, Healy JM and Stanton M (2005) Nucleic acid aptamers for target validation and therapeutic applications. J Biomol Tech 16, 224-234
18. Bates PJ, Laber DA, Miller DM, Thomas SD and Trent JO (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86, 151-164
19. Tajrishi MM, Tuteja R and Tuteja N (2011) Nucleolin: The most abundant multifunctional phosphoprotein of nucleolus. Commun Integr Biol 4, 267-275
20. Zhu J, Huang H, Dong S, Ge L and Zhang Y (2014) Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges. Theranostics 4, 931-944
21. Laber DA, Sharma VR, Bhupalam L, Taft B, Hendler FJ and Barnhart KM (2005) Update on the first phase I study of AGRO100 in advanced cancer. J Clin Oncol 23, 3064
22. Ni X, Castanares M, Mukherjee A and Lupold SE (2011) Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 18, 4206-4214
23. Nagasawa T, Hirota S, Tachibana K et al (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635-638
24. Sun X, Cheng G, Hao M et al (2010) CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29, 709-722
25. Shum KT, Zhou J and Rossi JJ (2013) Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther 4, 872-890
26. Hoellenriegel J, Zboralski D, Maasch C et al (2014) The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 123, 1032-1039
27. Liu SC, Alomran R, Chernikova SB et al (2014) Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro Oncol 16, 21-28
28. Zhou J and Rossi JJ (2014) Cell-type-specific, Aptamerfunctionalized Agents for Targeted Disease Therapy. Mol Ther Nucleic Acids 3, e169
29. Bruno JG (2013) A review of therapeutic aptamer conjugates with emphasis on new approaches. Pharmaceuticals (Basel) 6, 340-357
30. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA and Langer R (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64, 7668-7672
31. Farokhzad OC, Cheng J, Teply BA et al (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103, 6315-6320
32. Yu C, Hu Y, Duan J et al (2011) Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One 6, e24077
33. McNamara JO, Andrechek ER, Wang Y et al (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24, 1005-1015
34. Leal M, Sapra P, Hurvitz SA et al (2014) Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci 1321, 41-54
35. Perez HL, Cardarelli PM, Deshpande S et al (2014) Antibody-drug conjugates: current status and future directions. Drug Discov Today 19, 869-881
36. Shigdar S, Macdonald J, O'Connor M et al (2013) Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors (Basel) 13, 13624-13637
37. Griffin LC, Tidmarsh GF, Bock LC, Toole JJ and Leung LL (1993) In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81, 3271-3276
38. Davydova AS, Vorobjeva MA and Venyaminova AG (2011) Escort aptamers: new tools for the targeted delivery of therapeutics into cells. Acta Naturae 3, 12-29
39. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR and Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5, 123-132
40. Lakhin AV, Tarantul VZ and Gening LV (2013) Aptamers: problems, solutions and prospects. Acta Naturae 5, 34-43
41. Healy JM, Lewis SD, Kurz M et al (2004) Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 21, 2234-2246
42. Ruggiero A, Villa CH, Bander E et al (2010) Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A 107, 12369-12374
43. Burmeister PE, Lewis SD, Silva RF et al (2005) Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. Chem Biol 12, 25-33
44. Shapiro A and Lafond A (2012) Anti-VEGF state of the union. Retina Today Jan/Feb, 32-34
45. Kaiser PK, Cruess AF, Bogaert P, Khunti K and Kelly SP (2012) Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 250, 1563-1571